Trial Profile

An open-label, single-arm, dose-escalation and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SC0245 in patients with advanced malignant solid tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Jul 2024 New trial record
04 Jun 2024 Results (n=27; As of the data cut-off-date of January 10, 2024) assessing the safety, tolerability, pharmacokinetics and preliminary efficacy of the ATR inhibitor SC0245 in advanced solid malignancies, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com